ScreenerHero
IPHInnate Pharma S.A.
EPA · FR · Healthcare · Biotechnology · innate-pharma.com
1.910EUR+8.40%Mkt Cap: 231.66M $P/E: —

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which …

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap231.66M $
Enterprise Value168.71M $
Revenue (TTM)9.79M $
Gross Profit-37.63M $
Net Income (TTM)-53.45M $
Revenue/Share0.1098 USD
Last Price1.910 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees164
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010331421
Valuation
P/E (Trailing)—
P/E (Forward)0.83
PEG—
EV/EBITDA-2.91
EV/Revenue17.24
P/S—
P/B-7.67
EPS (TTM)-0.55
EPS (Forward)2.15
52W Range
1.03068% of range2.330
52W High2.330 EUR
52W Low1.030 EUR
Profitability
Gross Margin0.00%
Oper. Margin-689.55%
EBITDA Margin0.00%
Profit Margin-1764.51%
ROE226.58%
ROA-78.41%
Growth
Revenue Growth-46.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.39M $
CapEx (TTM)2.56M $
FCF Margin-378.39%
FCF Yield-15.99%
Net Debt-12.76M $
Net Debt/EBITDA0.22
Balance Sheet
Debt/Equity-1.04
Current Ratio1.27
Quick Ratio1.14
Book Value/Sh-0.2320 EUR
Cash/Share0.3660 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.900 EUR
Upside (mean)+208.9%
Target Range5.600 EUR – 6.200 EUR
€5.600+208.9% to mean€6.200
# Analysts2
Ownership
Shares Out.93.90M
Float70.57M
Insiders17.46%
Institutions10.70%
Technical
SMA 501.635 (+16.8%)
SMA 2001.499 (+27.4%)
Beta0.86
S&P 52W Chg18.16%
Avg Vol (30d)563.21K
Avg Vol (10d)1.47M
Technical Indicators
RSI (14)52.3
MACD0.0702
MACD Signal0.0681
MACD Hist.+0.0022
BB Upper2.130 EUR
BB Middle1.715 EUR
BB Lower1.300 EUR
BB Width48.39%
ATR (14)0.1289 EUR
Vol Ratio (20d)0.57x